Tackling Endocrine Resistance in Breast Cancer
This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.
In this video, Ingrid A. Mayer, MD, MSCI, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses mechanisms of acquired and upfront endocrine resistance in estrogen receptor (ER)-positive breast cancer as well as research into strategies for overcoming these types of resistance, including targeting the mTOR and PI3K pathways.
Mayer spoke on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia
June 13th 2025Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.
